NeoGenomics, Inc. (NEO) News

NeoGenomics, Inc. (NEO): $14.24

0.35 (+2.52%)

POWR Rating

Component Grades








Filter NEO News Items

NEO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NEO News Highlights

  • For NEO, its 30 day story count is now at 3.
  • Over the past 23 days, the trend for NEO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NEO are FL.

Latest NEO News From Around the Web

Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.

S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December

The S&P 500 came within inches of a record high Thursday, but had to settle for a minute gain as the stock market faded and small caps broke a trend of outperformance. The S&P 500 climbed less than 0.1%. The Nasdaq composite closed fractionally lower after erasing modest gains.

Yahoo | December 28, 2023

NeoGenomics to Appeal Ruling

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary ...

Yahoo | December 28, 2023

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual ...

Yahoo | December 5, 2023

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New ...

Yahoo | November 14, 2023

Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 13, 2023

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call — Third Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note this call is being recorded, and an audio replay will be […]

Yahoo | November 7, 2023

Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Yahoo | November 7, 2023

NeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023

Net loss decreases by 50% and Adjusted EBITDA increases by 129% Year-over-Year

Yahoo | November 6, 2023

NeoGenomics Reports Third Quarter 2023 Results

Third Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ...

Yahoo | November 6, 2023

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 1, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!